Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - clozapine (unii: j60ar2ikic) (clozapine - unii:j60ar2ikic) - clozapine 25 mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - clozapine - oral solution - 20mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - clozapine - oral suspension - 20mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - clozapine - oral suspension - 50mg/1ml

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 200 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate; magnesium stearate; povidone; microcrystalline cellulose - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 200 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; povidone; lactose monohydrate; sodium starch glycollate - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; sodium starch glycollate - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 50 mg - tablet - excipient ingredients: sodium starch glycollate; lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; magnesium stearate; sodium starch glycollate; microcrystalline cellulose - indications as at 22 october 2003: treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; povidone; sodium starch glycollate - indications as at 22 october 2003: treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).